$ZURA News
Last published 4d ago
- 4d agoZURAZura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis SuppurativaBusiness WireHENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its Phase 2 TibuSHIELD study, which evaluated tibulizumab (ZB-106) in adults with moderate-to-severe hid ...
- 2w agoZURAZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious
- 2w agoZURAZura Bio Ltd - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 2w agoZURAZura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate UpdatesBusiness WireTibuSHIELD topline data in hidradenitis suppurativa (HS) remains on track for Q4 2026; enrollment completed with 247 participants randomized, exceeding target TibuSURE topline data in systemic sclerosis (SSc)
- 2mo agoZURAZura Bio to Participate in the Cantor Global Healthcare ConferenceBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 2mo agoZURAZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious
- 3mo agoZURAZura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate UpdatesBusiness WireTibuSHIELD enrollment complete, exceeding initial enrollment target with 247 participants randomized in HS; topline data expected Q4 2026 TibuSURE enrollment complete, exceeding initial enrollment target with 91
- 4mo agoZURAZura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab ProgramBusiness WireTibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical development TibuSHIELD has completed enrollment, exceeding enrollment target with 247 participants randomized in HS;
- 6mo agoZURAZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 6mo agoZURAZura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business OfficerBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
- 6mo agoZURAZura Bio Reports First Quarter 2026 Financial Results and Recent Corporate UpdatesBusiness WireContinuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated
- 6mo agoZURAZura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Business WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 7mo agoZURAZura Bio Reports Full Year 2025 Financial Results and Recent Corporate UpdatesBusiness WireAdvancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from
- 8mo agoZURAZura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World CongressBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
- 8mo agoZURAZura Bio to Participate in Upcoming Investor ConferencesBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 8mo agoZURAZura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
- 8mo agoZURAZura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsBusiness WireZura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
- 8mo agoZURAZura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsBusiness WireZura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
- 8mo agoZURAZura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of DirectorsBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 9mo agoZURAZura Bio to Participate in the Guggenheim Emerging Outlook: Biotech SummitBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 9mo agoZURAZura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive OfficerBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating
- 1y agoZURAZura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate UpdatesBusiness WireContinued advancement of two Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with topline data expected in the second half of
- 1y agoZURAZura Bio to Participate in the Cantor Fitzgerald Global Healthcare ConferenceBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today
- 1y agoZURAZura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesBusiness WireInitiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS) in Q2 2025 Continued progress in the Phase 2 TibuSURE clinical study
- 1y agoZURAZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported
- 1y agoZURAZura Bio Announces Chief Financial Officer TransitionBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment
- 1y agoZURAZura Bio to Present at the Jefferies Global Healthcare ConferenceBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today
- 1y agoZURAZura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaBusiness WireTibuSHIELD has launched with the activation of its first clinical site This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with
- 1y agoZURAZura Bio Reports First Quarter 2025 Financial Results and Recent Corporate UpdatesBusiness WireAdvanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis
- 1y agoZURAZura Bio Reports Full Year 2024 Financial Results and Recent Corporate UpdatesBusiness WireAchieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis
- 1y agoZURAZura Bio to Present at the Leerink Partners Global Healthcare ConferenceBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior
- 1y agoZURAZura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic SclerosisBusiness WireTibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio Limited (NASDAQ:ZURA)
- 1y agoZURAZura Bio to Present at the Piper Sandler 36th Annual Healthcare ConferenceBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior
- 1y agoZURAZura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic SclerosisBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a
- 2y agoZURAZura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate UpdatesBusiness WireExpect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2
- 2y agoZURAZura Bio to Participate in Two Upcoming Investor Conferences in NovemberBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior
- 2y agoZURAZura Bio to Present at Three Upcoming Investor Conferences in SeptemberBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior
- 2y agoZURAZura Bio Reports Second Quarter 2024 Financial Results and Recent Business HighlightsBusiness WirePresented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating
- 2y agoZURAZura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding WarrantsBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has completed
- 2y agoZURAZura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its WarrantsBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the expiration and
- 2y agoBRNSRCUSSGMTSNDX+2Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of DirectorsGlobeNewswireSAN MATEO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
- 2y agoZURAZura Bio Commences Warrant Exchange Offer and Consent SolicitationBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it has commenced
- 2y agoZURAZura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024Business WireTibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren's syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A and BAFF in a
- 2y agoZURAZura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and ImmunologyBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the formation of a Scientific Advisory
- 2y agoZURAZura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024Business WireNovel, dual-pathway antibody targeting IL-17A and BAFF is expected to enter Phase 2 development in systemic sclerosis in Q4 2024 and hidradenitis suppurativa in Q2 2025 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a
- 2y agoZURAZura Bio Announces Participation in June Investor ConferencesBusiness WireZura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will
- 2y agoZURAZura Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness WireEnded Q1 2024 with $89.8 million in cash and closed oversubscribed $112.5 million private placement in April 2024 from new and existing leading life sciences institutional investors Appointed Robert Lisicki as CEO
- 2y agoZURAZura Bio Announces Oversubscribed $112.5 Million Private PlacementBusiness Wire- Financing includes new and existing leading life sciences institutional investors - Strengthened balance sheet expected to fund operations through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical
- 2y agoZURAZura Bio Announces Robert Lisicki as CEO and DirectorBusiness Wire- Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director - Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience - Outstanding
- 2y agoZURAZura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive OfficerBusiness WireSignificant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab